Cancer Science最新文献_第6页

FN1 Immunoregulation in Glioblastoma: Insights From Neutrophil-Centric Studies 胶质母细胞瘤中的FN1免疫调节：来自中性粒细胞中心研究的见解。

IF 4.5 2区医学

Cancer Science Pub Date : 2025-03-07 DOI: 10.1111/cas.70041

Xiangtian Meng, Xusen Yang, Junle Zhu, Huairui Chen, Chun Luo, Fenglin Zhang, Qin Zhang, Jingliang Ye

{"title":"FN1 Immunoregulation in Glioblastoma: Insights From Neutrophil-Centric Studies","authors":"Xiangtian Meng, Xusen Yang, Junle Zhu, Huairui Chen, Chun Luo, Fenglin Zhang, Qin Zhang, Jingliang Ye","doi":"10.1111/cas.70041","DOIUrl":"10.1111/cas.70041","url":null,"abstract":"Neutrophils, as key components of the tumor microenvironment, play a crucial role in cancer progression and prognosis. This study aimed to identify a neutrophil-related gene signature to improve prognostic predictions and explore potential immunotherapy targets for glioblastoma multiforme (GBM) patients. Through co-expression analysis, 60 neutrophil-associated genes were identified, showing significant enrichment in 159 Gene Ontology terms and eight KEGG pathways. Among these, 10 genes were significantly associated with patient survival, leading to the development of a six-gene risk model termed the Neutrophil-Related Gene Prognostic Index (NRGPI). The NRGPI predicted overall survival (OS) in both training and validation cohorts (p < 0.05), with enhanced prognostic accuracy when combined with clinicopathological factors. Higher NRGPI scores were correlated with worse OS, increased mortality, and more aggressive disease progression. Immune profiling linked NRGPI to immune cell infiltration, immune checkpoint expression, and tumor mutation burden, suggesting its potential in identifying candidates for immunotherapy. Among the identified genes, FN1 emerged as a central regulator, associated with immune cell composition and poor prognosis. Pan-cancer analysis revealed consistent upregulation of FN1 across cancer types, underscoring its broad clinical relevance. Additionally, tissue microarray analysis using multiplex immunofluorescence on 84 GBM samples confirmed co-expression of FN1, SDC1, and TWIST1, with higher levels associated with reduced survival. These findings establish NRGPI as a valuable prognostic biomarker for GBM, offering novel insights into the immune landscape and positioning FN1 as a promising therapeutic target for further investigation in GBM treatment.","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 6","pages":"1758-1772"},"PeriodicalIF":4.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GGCT Inhibits Ferroptosis in PTC Cells by Upregulating p53 Through RPS15A GGCT通过RPS15A上调p53抑制PTC细胞铁下垂。

IF 4.5 2区医学

Cancer Science Pub Date : 2025-03-05 DOI: 10.1111/cas.70039

Hui-min Zhang, Han-ning Li, Enbo Qi, Yang Yang, Huiping Ma, Jie Ma, Xiwen Xiong, Jun Wang, Zhi-fang Yang, Xing-hua Liao

{"title":"GGCT Inhibits Ferroptosis in PTC Cells by Upregulating p53 Through RPS15A","authors":"Hui-min Zhang, Han-ning Li, Enbo Qi, Yang Yang, Huiping Ma, Jie Ma, Xiwen Xiong, Jun Wang, Zhi-fang Yang, Xing-hua Liao","doi":"10.1111/cas.70039","DOIUrl":"10.1111/cas.70039","url":null,"abstract":"γ-Glutamine cyclotransferase (GGCT) is an enzyme involved in the metabolic cycle of glutathione (GSH). Abnormal GSH metabolism is mostly related to ferroptosis. However, the mechanisms supporting aberrant GGCT expression in PTC remain to be investigated. In this study, we found that GGCT knockdown inhibited GSH synthesis and promoted malondialdehyde (MDA) and reactive oxygen species (ROS) accumulation, thereby promoting ferroptosis in papillary thyroid cancer cells. Pro-GA, the specific inhibitor of GGCT, inhibited the subcutaneous tumor formation of K1 cells. IP combined with LC–MS/MS showed an interaction between GGCT and RPS15A. RPS15A is highly expressed in PTC tissues and cells, and GGCT promotes the stability of RPS15A. Knockdown of RPS15A promoted p53 expression, which in turn inhibited SLC7A11 expression, resulting in ferroptosis, while overexpression of RPS15A reversed GGCT-induced ferroptosis. In addition, miR-205-5p targeted the 3’ UTR of GGCT to inhibit GGCT-mediated ferroptosis, tumor growth, and lung metastasis. In conclusion, we found that knockdown of GGCT promoted ferroptosis in PTC cells. Mechanistically, GGCT interacts with RPS15A, and GGCT promotes the protein stability of RPS15A. Knockdown of RPS15A promotes p53 expression and inhibits SLC7A11 expression, thereby inhibiting GSH synthesis. The upstream mechanism of GGCT regulation showed that miR-205-5p inhibited GGCT protein expression by targeting the 3′ UTR of GGCT.","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 6","pages":"1592-1603"},"PeriodicalIF":4.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors 利用溴域和超末端结构域抑制剂克服奥西替尼耐药性的新方法。

IF 4.5 2区医学

Cancer Science Pub Date : 2025-03-04 DOI: 10.1111/cas.70032

Yosuke Miyashita, Ken Tajima, Kenta Izumi, Naohisa Matsumoto, Daisuke Hayakawa, Ikuko Takeda Nakamura, Isana Katayama, Adityo Wibowo, Hironari Matsuda, Wira Winardi, Bagus Radityo Amien, Yoichiro Mitsuishi, Fumiyuki Takahashi, Kohta Nakamura, Ken Uchibori, Noriko Yanagitani, Takuo Hayashi, Kazuya Takamochi, Kenji Suzuki, Ryohei Katayama, Kazuhisa Takahashi

{"title":"Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors","authors":"Yosuke Miyashita, Ken Tajima, Kenta Izumi, Naohisa Matsumoto, Daisuke Hayakawa, Ikuko Takeda Nakamura, Isana Katayama, Adityo Wibowo, Hironari Matsuda, Wira Winardi, Bagus Radityo Amien, Yoichiro Mitsuishi, Fumiyuki Takahashi, Kohta Nakamura, Ken Uchibori, Noriko Yanagitani, Takuo Hayashi, Kazuya Takamochi, Kenji Suzuki, Ryohei Katayama, Kazuhisa Takahashi","doi":"10.1111/cas.70032","DOIUrl":"10.1111/cas.70032","url":null,"abstract":"Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, is the first-line therapy for lung cancer harboring EGFR mutations. The mechanisms underlying osimertinib resistance are diverse, with approximately half remaining unknown. Epigenetic dysregulation is implicated in drug resistance; however, the mechanisms remain unclear. Therefore, we investigated epigenetic involvement in osimertinib resistance and its therapeutic potential. We established osimertinib-resistant cells and used an assay for transposase-accessible chromatin using sequencing to evaluate chromatin accessibility, finding significant changes post-resistance. Combining the assay for transposase-accessible chromatin and RNA sequencing data, we identified FGF1 as a resistance-related gene regulated by histone modifications. FGF1 induced osimertinib resistance, and its suppression attenuated resistance. Bromodomain and extra-terminal domain inhibitors combined with osimertinib overcame osimertinib resistance by reducing FGF1 expression. Increased FGF1 expression was observed in osimertinib-resistant clinical samples. This combination therapy was effective in cell lines and mouse xenograft models. These results suggest targeting histone modifications using bromodomain and extra-terminal domain inhibitors as a novel approach to overcoming osimertinib resistance.","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 5","pages":"1392-1404"},"PeriodicalIF":4.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Feasibility of Intratumoral Administration With EPHB4-CAR-T Cells for the Treatment of Oral Squamous Cell Carcinoma 肿瘤内注射EPHB4-CAR-T细胞治疗口腔鳞状细胞癌的可行性

IF 4.5 2区医学

Cancer Science Pub Date : 2025-03-03 DOI: 10.1111/cas.70023

Yusuke Ito, Toshihiro Suzuki, Manami Shimomura, Kazumasa Takenouchi, Kazunobu Ohnuki, Kayoko Shoda, Yuka Kenmochi, Shigeki Yagyu, Kazuto Matsuura, Ryuichi Hayashi, Tetsuya Nakatsura

{"title":"Feasibility of Intratumoral Administration With EPHB4-CAR-T Cells for the Treatment of Oral Squamous Cell Carcinoma","authors":"Yusuke Ito, Toshihiro Suzuki, Manami Shimomura, Kazumasa Takenouchi, Kazunobu Ohnuki, Kayoko Shoda, Yuka Kenmochi, Shigeki Yagyu, Kazuto Matsuura, Ryuichi Hayashi, Tetsuya Nakatsura","doi":"10.1111/cas.70023","DOIUrl":"10.1111/cas.70023","url":null,"abstract":"Oral squamous cell carcinoma (OSCC) represents the most common type of oral cancer, and its prognosis remains poor. In this study, we found that almost OSCC cases showed high Ephrin type-B receptor 4 (EPHB4) expression that was mainly localized on the membrane of tumor cells. Therefore, EPHB4 represents a potential target of chimeric antigen receptor (CAR) T cell therapy for OSCC treatment. Because the oral cavity can be directly accessed, local administration of CAR-T cells is feasible for treating OSCC. In this study, we investigated the efficacy of intratumoral injection of EPHB4-specific CAR-T cells in OSCC using xenograft models. To evaluate the anti-tumor effect, the SAS OSCC cell line or an OSCC patient-derived xenograft (PDX) tumor was subcutaneously implanted into NOD SCID gamma mice, and EPHB4-CAR-T cells were intratumorally injected twice. As expected, administration of CAR-T cells suppressed tumor growth of both SAS cells and PDX tumor. EPHB4 expression in tumor tissues was attenuated by CAR-T cell treatment, which was accompanied by a reduction in tumor area and accumulation of CAR-T cells. Our findings suggest that intratumoral injection of EPHB4-CAR-T cells represents a potential therapeutic strategy for OSCC.","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 5","pages":"1227-1238"},"PeriodicalIF":4.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Induction Camrelizumab and Modified TPF (Nab-Paclitaxel, Cisplatin, and S-1) in Locoregionally Advanced Nasopharyngeal Carcinoma Camrelizumab和改良TPF （nab -紫杉醇、顺铂和S-1）在局部区域晚期鼻咽癌中的诱导作用

IF 4.5 2区医学

Cancer Science Pub Date : 2025-03-03 DOI: 10.1111/cas.70037

Yi-Feng Yu, Ya-Qing Dai, Zong-Kai Zhang, Guan-Zhong Lu, Qin Lin, San-Gang Wu

{"title":"Induction Camrelizumab and Modified TPF (Nab-Paclitaxel, Cisplatin, and S-1) in Locoregionally Advanced Nasopharyngeal Carcinoma","authors":"Yi-Feng Yu, Ya-Qing Dai, Zong-Kai Zhang, Guan-Zhong Lu, Qin Lin, San-Gang Wu","doi":"10.1111/cas.70037","DOIUrl":"10.1111/cas.70037","url":null,"abstract":"Induction chemo-immunotherapy has emerged as a potential treatment option for locoregionally advanced nasopharyngeal carcinoma (LANPC). This study aimed to evaluate the efficacy and safety of camrelizumab combined with modified TPF (nab-paclitaxel, cisplatin, and S-1) as induction chemo-immunotherapy in LANPC. Patients with stage T1-4N2-3M0 NPC who received induction chemo-immunotherapy were enrolled from July 2023 to May 2024. They underwent three cycles of chemo-immunotherapy, including camrelizumab 200 mg on day 1, nab-paclitaxel 260 mg/m2 on day 1, cisplatin 25 mg/m2 on days 1–3, and oral S-1 40–60 mg twice daily from days 1 to 14, every 21 days. The primary endpoint was the complete response (CR) rate, while secondary endpoints included the safety and objective response rate (ORR). A total of 30 patients were enrolled, with 29 (96.7%) completing three cycles of induction chemo-immunotherapy. The CR rate was 41.4% (12/29), achieving the predefined endpoint. The CR rate for the primary nasopharyngeal tumor and cervical lymph nodes was both 65.5% (19/29). Seventeen patients achieved a partial response (PR), resulting in an ORR of 100%. Grade 3 or 4 chemotherapy-related adverse events occurred in 26.6% of patients. Immune-related adverse events of any grade were reported in 20 (66.7%) patients, including reactive cutaneous capillary endothelial proliferation in 10 patients (40.0%), all of which were Grade 1 or 2. One patient (3.5%) experienced a Grade 3 rash. No treatment-related deaths occurred. Our study suggests that induction chemo-immunotherapy of camrelizumab plus modified TPF demonstrated an excellent CR rate and an acceptable safety profile in patients with LANPC.Trial Registration: ChiCTR240008603","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 6","pages":"1616-1626"},"PeriodicalIF":4.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron-Dependent PI3K/AKT/mTOR Signaling Pathway 转铁蛋白受体通过激活铁依赖性 PI3K/AKT/mTOR 信号通路促进子宫内膜癌增殖

IF 4.5 2区医学

Cancer Science Pub Date : 2025-03-01 DOI: 10.1111/cas.70015

Yufei Yang, Ying Ning, Yu Chen, Tian Tian, Xinyan Gao, Yan Kong, Ke Lei, Zhumei Cui

{"title":"Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron-Dependent PI3K/AKT/mTOR Signaling Pathway","authors":"Yufei Yang, Ying Ning, Yu Chen, Tian Tian, Xinyan Gao, Yan Kong, Ke Lei, Zhumei Cui","doi":"10.1111/cas.70015","DOIUrl":"10.1111/cas.70015","url":null,"abstract":"Aberrant iron metabolism is frequently observed in cancers, including endometrial cancer (EC). However, the role of transferrin receptor (TFRC), a key regulator of iron metabolism, remains unclear in endometrial cancer. We found transferrin receptor expression was significantly upregulated in endometrial cancer tissues compared to adjacent nontumor tissues, and high transferrin receptor levels were associated with poor prognosis. Functional studies revealed that transferrin receptor knockdown impaired endometrial cancer cell proliferation in vitro and in vivo, while transferrin receptor overexpression enhanced endometrial cancer cell proliferation. Mechanistically, transferrin receptor activated the PI3K/AKT/mTOR signaling pathway, as its knockdown suppressed the pathway, and rapamycin, an mTOR inhibitor, reversed transferrin receptor-induced pathway activation and proliferation. Modulation of the labile iron pool by ferric ammonium citrate (FAC) or deferoxamine (DFO) rescued transferrin receptor-induced biological effects. Additionally, AURKA was identified as a regulator of transferrin receptor expression. These findings demonstrate the oncogenic role of transferrin receptor in endometrial cancer and suggest that targeting iron homeostasis and the PI3K/AKT/mTOR pathway may represent potential therapeutic strategies for endometrial cancer.","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 5","pages":"1352-1365"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights From Nonsense-Mediated mRNA Decay for Prognosis in Homologous Recombination-Deficient Ovarian Cancer 从无义基因介导的 mRNA 衰变洞察同源重组缺陷卵巢癌的预后

IF 4.5 2区医学

Cancer Science Pub Date : 2025-03-01 DOI: 10.1111/cas.70034

Lei Han, Jialing Liu, Runjiao Zhang, Yanan Cheng, Li Dong, Lijuan Wei, Juntian Liu, Ke Wang, Jinpu Yu

{"title":"Insights From Nonsense-Mediated mRNA Decay for Prognosis in Homologous Recombination-Deficient Ovarian Cancer","authors":"Lei Han, Jialing Liu, Runjiao Zhang, Yanan Cheng, Li Dong, Lijuan Wei, Juntian Liu, Ke Wang, Jinpu Yu","doi":"10.1111/cas.70034","DOIUrl":"10.1111/cas.70034","url":null,"abstract":"Not all ovarian cancer patients with homologous recombination deficiency, especially those with germline BRCA mutations, can benefit from platinum-based and targeted therapy. Our study aimed to determine the value of nonsense-mediated mRNA decay, which targeted these mutations. The retrospective analysis of 797 ovarian cancer patients was performed using two public cohorts and one in-house cohort. We developed a prediction algorithm for nonsense-mediated mRNA decay to discriminate between trigger and escape status, finding that escape status indicated a better prognosis. Subsequently, we analyzed differential gene expression and functional pathways between the two statuses and filtered 8 genes associated with the cell cycle. Then the optimized key gene model was built using integrated machine learning algorithms (mean AUC > 0.89), which had a higher independent prognostic value for ovarian cancer with germline BRCA variants or homologous recombination deficiency than the nonsense-mediated mRNA decay algorithm. Furthermore, we classified patients into high- and low-risk groups by the machine learning model and found that the low-risk group had a better prognosis with higher drug response and immune levels of activated dendritic cells than the high-risk controls. Our findings provide a perspective based on nonsense-mediated mRNA decay and cell cycle pathways to distinguish subtypes of germline BRCA or homologous recombination deficiency.","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 5","pages":"1449-1463"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High Antigenicity for Treg Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in Treg Cells Treg细胞的高抗原性通过在Treg细胞中高PD-1表达赋予PD-1阻断治疗抗性。

IF 4.5 2区医学

Cancer Science Pub Date : 2025-02-27 DOI: 10.1111/cas.70029

Hiroaki Matsuura, Takamasa Ishino, Toshifumi Ninomiya, Kiichiro Ninomiya, Kota Tachibana, Akiko Honobe-Tabuchi, Yoshinori Muto, Takashi Inozume, Youki Ueda, Kadoaki Ohashi, Yoshinobu Maeda, Joji Nagasaki, Yosuke Togashi

{"title":"High Antigenicity for Treg Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in Treg Cells","authors":"Hiroaki Matsuura, Takamasa Ishino, Toshifumi Ninomiya, Kiichiro Ninomiya, Kota Tachibana, Akiko Honobe-Tabuchi, Yoshinori Muto, Takashi Inozume, Youki Ueda, Kadoaki Ohashi, Yoshinobu Maeda, Joji Nagasaki, Yosuke Togashi","doi":"10.1111/cas.70029","DOIUrl":"10.1111/cas.70029","url":null,"abstract":"Regulatory T (Treg) cells have an immunosuppressive function, and programmed death-1 (PD-1)-expressing Treg cells reportedly induce resistance to PD-1 blockade therapies through their reactivation. However, the effects of antigenicity on PD-1 expression in Treg cells and the resistance to PD-1 blockade therapy remain unclear. Here, we show that Treg cells gain high PD-1 expression through an antigen with high antigenicity. Additionally, tumors with high antigenicity for Treg cells were resistant to PD-1 blockade in vivo due to PD-1+ Treg-cell infiltration. Because such PD-1+ Treg cells have high cytotoxic T lymphocyte antigen (CTLA)-4 expression, resistance could be overcome by combination with an anti-CTLA-4 monoclonal antibody (mAb). Patients who responded to combination therapy with anti-PD-1 and anti-CTLA-4 mAbs sequentially after primary resistance to PD-1 blockade monotherapy showed high Treg cell infiltration. We propose that the high antigenicity of Treg cells confers resistance to PD-1 blockade therapy via high PD-1 expression in Treg cells, which can be overcome by combination therapy with an anti-CTLA-4 mAb.","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 5","pages":"1214-1226"},"PeriodicalIF":4.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytoplasmic Vacuolization: A Fascinating Morphological Alteration From Cellular Stress to Cell Death 细胞质空泡化：从细胞应激到细胞死亡的一个令人着迷的形态学改变。

IF 4.5 2区医学

Cancer Science Pub Date : 2025-02-27 DOI: 10.1111/cas.70013

Xiaoxu Wen, Hongru Ma

引用次数: 0

EPHB2 Promotes the Progression of Oral Squamous Cell Carcinoma Cells Through the Activation of VPS4A-Mediated Autophagy EPHB2通过激活vps4a介导的自噬促进口腔鳞状细胞癌细胞的进展。

IF 4.5 2区医学

Cancer Science Pub Date : 2025-02-27 DOI: 10.1111/cas.70033

Yongchun Peng, Jianbo Zhang, Haoxuan Guo, Zhijing He, Yi Jiang, Sheng Zhang, Tengfei Fan

{"title":"EPHB2 Promotes the Progression of Oral Squamous Cell Carcinoma Cells Through the Activation of VPS4A-Mediated Autophagy","authors":"Yongchun Peng, Jianbo Zhang, Haoxuan Guo, Zhijing He, Yi Jiang, Sheng Zhang, Tengfei Fan","doi":"10.1111/cas.70033","DOIUrl":"10.1111/cas.70033","url":null,"abstract":"Oral squamous cell carcinoma (OSCC) is a prevalent type of head and neck neoplasm distinguished by a high risk of metastasis and a poor prognosis. Nevertheless, the fundamental mechanisms of OSCC cell proliferation and metastasis remain poorly understood. Autophagy, as the principal intracellular degradation system, has been implicated in OSCC progression; however, its underlying mechanism remains unclear. In this study, transcriptomic sequencing analysis was performed using both The Cancer Genome Atlas (TCGA) database and samples from OSCC patients and revealed significant upregulation of EPHB2 expression, which is positively correlated with OSCC metastasis and a poor prognosis. In subsequent studies, we observed that the knockdown of EPHB2 resulted in the blockade of autophagic flux due to impaired lysosomal function, leading to inhibited proliferation, migration, and invasion in OSCC cells. Furthermore, the knockdown of EPHB2 significantly suppressed the expression of VPS4A, a key mediator that facilitates autolysosomal degradation. The overexpression of VPS4A restored lysosomal function and autophagic flux, thereby attenuating the inhibitory effects of EPHB2 knockdown on OSCC cell progression. The findings of this study demonstrate that the molecular mechanism underlying EPHB2 regulation of autophagic flux to promote OSCC progression is by regulating VPS4A activity and that EPHB2 may be a diagnostic biomarker and therapeutic target for OSCC prevention and treatment.","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 5","pages":"1308-1323"},"PeriodicalIF":4.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0